CO2017005391A2 - Composiciones de antibiótico - Google Patents

Composiciones de antibiótico

Info

Publication number
CO2017005391A2
CO2017005391A2 CONC2017/0005391A CO2017005391A CO2017005391A2 CO 2017005391 A2 CO2017005391 A2 CO 2017005391A2 CO 2017005391 A CO2017005391 A CO 2017005391A CO 2017005391 A2 CO2017005391 A2 CO 2017005391A2
Authority
CO
Colombia
Prior art keywords
acetyl
solutions
amino acid
vancomycin
alanine
Prior art date
Application number
CONC2017/0005391A
Other languages
English (en)
Spanish (es)
Inventor
Ivona Jasprica
Sabina Keser
Katarina Pindric
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017005391(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of CO2017005391A2 publication Critical patent/CO2017005391A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CONC2017/0005391A 2014-11-06 2017-05-26 Composiciones de antibiótico CO2017005391A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076400P 2014-11-06 2014-11-06
US201562168749P 2015-05-30 2015-05-30
PCT/EP2015/075918 WO2016071495A1 (en) 2014-11-06 2015-11-06 Glycopeptide compositions

Publications (1)

Publication Number Publication Date
CO2017005391A2 true CO2017005391A2 (es) 2017-10-31

Family

ID=54478023

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0005391A CO2017005391A2 (es) 2014-11-06 2017-05-26 Composiciones de antibiótico

Country Status (30)

Country Link
US (7) US10188697B2 (en:Method)
EP (4) EP4147710A1 (en:Method)
JP (2) JP6797795B2 (en:Method)
KR (2) KR102763211B1 (en:Method)
CN (1) CN107073072B (en:Method)
AU (1) AU2015341763B2 (en:Method)
BR (1) BR112017009405B1 (en:Method)
CA (1) CA2964524A1 (en:Method)
CL (1) CL2017001139A1 (en:Method)
CO (1) CO2017005391A2 (en:Method)
CR (1) CR20170234A (en:Method)
CY (2) CY1122960T1 (en:Method)
DK (2) DK3215173T3 (en:Method)
EA (1) EA035368B1 (en:Method)
ES (2) ES2852550T3 (en:Method)
HR (2) HRP20200101T1 (en:Method)
HU (2) HUE053347T2 (en:Method)
IL (1) IL252120B (en:Method)
MX (1) MX387229B (en:Method)
NZ (1) NZ731955A (en:Method)
PH (1) PH12017500720A1 (en:Method)
PL (2) PL3542812T3 (en:Method)
PT (2) PT3542812T (en:Method)
RS (2) RS59851B1 (en:Method)
SA (1) SA517381446B1 (en:Method)
SG (1) SG11201703568WA (en:Method)
SI (2) SI3215173T1 (en:Method)
TN (1) TN2017000182A1 (en:Method)
WO (1) WO2016071495A1 (en:Method)
ZA (1) ZA201702767B (en:Method)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ731955A (en) 2014-11-06 2023-07-28 Xellia Pharmaceuticals Aps Glycopeptide compositions
EP3393491B1 (en) * 2015-12-24 2025-04-16 Universiteit Leiden Composition and method for treating infections caused by vancomycin-resistant infectious agents in a subject
CA3021935A1 (en) * 2016-05-09 2017-11-16 Xellia Pharmaceuticals Aps Stabilized glycopeptide antibiotic formulations
EP3544616A4 (en) * 2016-11-23 2020-12-09 Gufic Biosciences Limited LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF DALBAVANCIN
JP7118412B2 (ja) * 2017-07-31 2022-08-16 東洋製薬化成株式会社 バンコマイシン懸濁液充填カプセル製剤
CN109725101B (zh) * 2017-10-31 2021-11-19 正大天晴药业集团股份有限公司 盐酸特拉万星原料中有关物质的检测方法
CN109078001B (zh) * 2018-09-21 2021-05-07 深圳浦瑞健康科技有限公司 一种万古霉素纳米脂质体组合物及其制备方法
AU2020237983A1 (en) 2019-03-08 2021-10-07 Emphascience, Inc. Stable pharmaceutical formulations of peptide and protein drugs
US12343373B2 (en) * 2020-10-30 2025-07-01 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014969A1 (en) * 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014965A1 (en) * 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
WO2022234036A1 (en) * 2021-05-07 2022-11-10 Xellia Pharmaceuticals Aps Oral liquid vancomycin formulations
CN115804832A (zh) * 2021-09-14 2023-03-17 海南普利制药股份有限公司 一种万古霉素水溶液组合物
JPWO2023171588A1 (en:Method) * 2022-03-08 2023-09-14
GB202207344D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
GB202207345D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
WO2024079224A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition
US12070485B2 (en) 2022-10-12 2024-08-27 Xellia Pharmaceuticals Aps Liquid dalbavancin compositions
WO2025006267A1 (en) * 2023-06-26 2025-01-02 Venn Biosciences Corporation Peptide biomarkers for diagnosing primary sclerosing cholangitis or primary biliary cholangitis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670258A (en) 1984-02-10 1987-06-02 Vanderbilt University Storable prepackaged aqueous solutions of vancomycin
UA43323C2 (uk) 1994-01-28 2001-12-17 Елі Ліллі Енд Компані Антибіотичні похідні глікопептидів, спосіб отримання та фармацевтична композиція
AU1407197A (en) 1995-12-01 1997-06-19 Eli Lilly And Company Stable vancomycin hydrochloride solutions
JPH1180021A (ja) 1997-09-02 1999-03-23 Kayaku:Kk バンコマイシン注射剤
US6800608B2 (en) 2001-06-22 2004-10-05 Beckman Coulter, Inc. Homogeneous assay of vancomycin using a stable particle-vancomycin conjugate, a novel rate enhancer, and a novel dose response modulator
US7022712B2 (en) * 2002-03-26 2006-04-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Solubilization of weak bases
GB0212622D0 (en) 2002-05-31 2002-07-10 Natural Technologies Group Ltd Bacterial transforming agent
CN1826129A (zh) * 2002-07-09 2006-08-30 尖端医疗有限公司 与异亮氨酸硼脯氨酸化合物相关的方法和组合物
AU2003248921A1 (en) 2002-07-09 2004-01-23 Point Therapeutics, Inc. Boroproline compound combination therapy
US6900175B2 (en) 2002-11-18 2005-05-31 Vicuron Pharmaceuticals Inc. Methods of administering dalbavancin for treatment of bacterial infections
PT1848413E (pt) 2005-02-14 2014-07-18 Venus Remedies Ltd Terapia de combinação parentérica para afecções infecciosas com bactérias resistentes a fármacos
CN1857716A (zh) * 2006-03-14 2006-11-08 浙江大学 注射用盐酸万古霉素及其制备方法
JP2008201778A (ja) 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
EP2231191A2 (en) * 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
JP2011080021A (ja) 2009-10-09 2011-04-21 Bridgestone Corp 熱可塑性エラストマー組成物及びその成形体
CA2836643C (en) * 2011-05-19 2017-11-14 Savara, Inc. Dry powder vancomycin compositions and associated methods
US20150182667A1 (en) 2012-08-08 2015-07-02 Vanderbilt University Composition with Biofilm Dispersal Agents
WO2014085526A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US9616098B2 (en) 2013-05-30 2017-04-11 Scidose, Llc Formulations of vancomycin
CN106573037A (zh) 2014-03-14 2017-04-19 库蒂斯制药公司 用于万古霉素口服液的组合物和方法
NZ731955A (en) 2014-11-06 2023-07-28 Xellia Pharmaceuticals Aps Glycopeptide compositions
CA3021935A1 (en) 2016-05-09 2017-11-16 Xellia Pharmaceuticals Aps Stabilized glycopeptide antibiotic formulations
US12343373B2 (en) 2020-10-30 2025-07-01 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution

Also Published As

Publication number Publication date
KR102763211B1 (ko) 2025-02-04
DK3215173T3 (da) 2020-03-23
EA201790997A1 (ru) 2017-09-29
HUE049857T2 (hu) 2020-10-28
US10849956B2 (en) 2020-12-01
AU2015341763A1 (en) 2017-06-08
CY1122960T1 (el) 2021-10-29
NZ731955A (en) 2023-07-28
CA2964524A1 (en) 2016-05-12
HRP20210342T8 (hr) 2022-01-21
ZA201702767B (en) 2018-12-19
EP3215173B8 (en) 2020-03-11
US12161690B2 (en) 2024-12-10
SI3542812T1 (sl) 2021-04-30
EP3215173B1 (en) 2020-01-01
EP3215173A1 (en) 2017-09-13
PT3215173T (pt) 2020-04-03
CN107073072A (zh) 2017-08-18
PL3542812T3 (pl) 2021-07-12
US11517609B2 (en) 2022-12-06
KR102603756B1 (ko) 2023-11-16
PT3542812T (pt) 2021-04-20
CR20170234A (es) 2018-01-15
PL3215173T3 (pl) 2020-05-18
US20210220433A1 (en) 2021-07-22
US10039804B2 (en) 2018-08-07
SA517381446B1 (ar) 2020-09-21
EP3542812B1 (en) 2021-01-13
EP3834837A1 (en) 2021-06-16
US11628200B2 (en) 2023-04-18
HRP20200101T1 (hr) 2020-04-03
BR112017009405B1 (pt) 2024-02-06
ES2769849T3 (es) 2020-06-29
RS59851B1 (sr) 2020-02-28
TN2017000182A1 (en) 2018-10-19
SI3215173T1 (sl) 2020-03-31
EA035368B1 (ru) 2020-06-03
EP3542812A1 (en) 2019-09-25
CL2017001139A1 (es) 2017-12-01
EP4147710A1 (en) 2023-03-15
US11000567B2 (en) 2021-05-11
US20220354927A1 (en) 2022-11-10
US20230158101A1 (en) 2023-05-25
ES2852550T3 (es) 2021-09-13
MX2017005749A (es) 2018-01-11
PH12017500720A1 (en) 2017-10-09
US20170348385A1 (en) 2017-12-07
JP2017533218A (ja) 2017-11-09
IL252120B (en) 2020-07-30
HRP20210342T1 (hr) 2021-04-30
AU2015341763B2 (en) 2019-01-17
US20190160142A1 (en) 2019-05-30
KR20230096142A (ko) 2023-06-29
CN107073072B (zh) 2021-06-18
WO2016071495A1 (en) 2016-05-12
US20200069768A1 (en) 2020-03-05
HUE053347T2 (hu) 2021-06-28
BR112017009405A2 (pt) 2018-01-02
IL252120A0 (en) 2017-07-31
US20180133286A1 (en) 2018-05-17
US10188697B2 (en) 2019-01-29
JP2020183424A (ja) 2020-11-12
JP7032488B2 (ja) 2022-03-08
CY1124011T1 (el) 2022-05-27
JP6797795B2 (ja) 2020-12-09
KR20170078830A (ko) 2017-07-07
MX387229B (es) 2025-03-04
SG11201703568WA (en) 2017-05-30
DK3542812T3 (da) 2021-04-12
RS61418B1 (sr) 2021-03-31

Similar Documents

Publication Publication Date Title
CO2017005391A2 (es) Composiciones de antibiótico
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
HUE039931T2 (hu) Szfingozin-1-foszfát receptor agonisták, azok elkészítési eljárásai, és azokat aktív ágensként tartalmazó gyógyszerészeti készítmények
UY35500A (es) Indazoles sustituidos con heteroarilo
EA201591809A1 (ru) Стабилизированный состав витамина d с модифицированным высвобождением и способ его введения
MX2020002693A (es) Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
UY35351A (es) Formulaciones acuosas estables de adalimumab
BR112016006326A2 (pt) formulação seca de uma vacina, uso de uma formulação seca, método para fabricação de uma formulação seca, e, vacina
BR112018002983A2 (pt) composição compreendendo uma lactama e um álcool
GT201700190A (es) Desacetoxitubulisina h y análogos de esta
MX382747B (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias.
MX2016005395A (es) Formulacion estable de insulina glulisina.
BR112017003219A2 (pt) formulação de acetato de abiraterona e métodos de uso
MX389178B (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
MX384877B (es) Composiciones de éster de colina de ácido lipoico y métodos de uso.
BR112017027721A2 (pt) formulação de alta concentração
MX391152B (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
MX2016016148A (es) Preparacion de rocuronio con estabilidad mejorada.
TW201613557A (en) Stable aqueous recombinant protein formulations
AR095398A1 (es) Formulaciones con oxidación reducida
CA3003108A1 (en) Storage stable composition comprising rifaximin alpha
MX2015005510A (es) Forma salina solida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
MX2018004138A (es) Metodos y formulaciones para reducir las emisiones de bovino.